DEPARTMENT OF HEALTH AND HUMAN SERVICES

**Food and Drug Administration** 

21 CFR Parts 510 and 520

Oral Dosage Form New Animal Drugs; Ivermectin and Pyrantel Pamoate

Chewable Tablets

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Heska Corp. The ANADA provides for use of chewable tablets containing ivermectin and pyrantel pamoate for prevention of heartworm disease and for treatment and control of certain gastrointestinal parasites in dogs.

**DATES:** This rule is effective [insert date of publication in the **Federal Register**].

FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for Veterinary Medicine (HFV–104), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301–827–8549, e-mail: *lluther@cvm.fda.gov*.

**SUPPLEMENTARY INFORMATION:** Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO 80525, filed ANADA 200–338 that provides for veterinary prescription use of TRI–HEART PLUS (ivermectin and pyrantel pamoate) Chewable Tablets for prevention of canine heartworm disease caused by *Dirofilaria immitis* and for treatment and control of ascarids (Toxocara canis, Toxascaris leonina) and hookworms (Ancylostoma caninum, A. braziliense, and Uncinaria stenocephala) in dogs. Heska Corp.'s TRI–HEART PLUS Chewable Tablets is

approved as a generic copy of Merial's HEARTGARD Plus Chewables, approved under NADA 140–971. ANADA 200–338 is approved as of August 13, 2003, and 21 CFR 520.1196 is amended to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In addition, Heska Corp. is not currently listed in the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for the firm.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

# **List of Subjects**

#### 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

### 21 CFR Part 520

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amended as follows:

## **PART 510—NEW ANIMAL DRUGS**

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding a new entry for "Heska Corp." and in the table in paragraph (c)(2) by numerically adding a new entry for "063604" to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

 $\blacksquare$  4. Section 520.1196 is amended by revising paragraph (b) to read as follows:

§ 520.1196 Ivermectin and pyrantel pamoate chewable tablets.

\* \* \* \* \*

(b) Sponsors. See Nos. 050604, 051311, and 063604 in  $\S\,510.600(c)$  of this chapter.

\* \* \* \* \*

Dated: September 15, 2003.

# Linda Tollefson,

 $Deputy\,Director,\,Center\,for\,Veterinary\,Medicine.$ 

[FR Doc. 03–????? Filed ??–??–03; 8:45 am]

BILLING CODE 4160-01-S